Business
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
– Announced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time –
About this update from Ironwood Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Announced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time –\n\n\n– Initiated rolling NDA submission; on track to be completed in Q3 2025 –\n\n\n– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 11% for full-year 2024 year-over-year –\n\n\n– 2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million –\n\n\n BOSTON--(BUSINESS WIRE)--\nIronwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results and recent business performance.\n\n\n“We believe that 2025 marks the beginning of a transformation for Ironwood that will lay the foundation for growth, long-term value creation, and the delivery of new medicines to rare disease and GI patients in need. We have taken strategic actions to position our organization for success, including streamlining our business operations and advancing the clinical development of apraglutide, while maintaining disciplined financial stewardship to drive cash flows, pay down our debt, and further strengthen our balance sheet,” said Tom McCourt, chief executive officer of Ironwood.\n\n\n\"We have initiated the rolling NDA submission for apraglutide, and we are working with urgency to complete the submission and prepare for potential launch. Our confidence in apraglutide continues to grow, especially in light of the data we shared in January from the open-label extension study. These results show a continued increase in clinical benefit over time, with 27 total apraglutide-dosed patients achieving enteral autonomy. Given these compelling new long-term data, we plan to include additional extension study data in our NDA to deliver a more robust, clinically differentiated, and comprehensive submission package. If approved, apraglutide would be the first and only once-weekly GLP-2 therapy, reinforcing its potential to become a blockbuster drug and significantly expand treatment options for SBS patients.”\n\n\nFourth Quarter and Full Year 2024 Financial Highlights1\n(in thousands, except for per share amounts)\n\n\n\n\n \n\n\n\n\n\n\nQ4 2024\n\n\n\n\n\n \n\nQ4 2023\n\n\n\n\n...